Survey results on the awareness of risk factors associated with Sodium Valproate (Epilim)
From December 9th 2019 - February 28th 2020, Epilepsy Ireland conducted a survey aimed at establishing awareness of the risks associated with the use of the drug sodium valproate (Epilim) in pregnancy and individuals’ experience of the various risk-reduction measures that have been put in place by authorities following campaigning on the issue by Epilepsy Ireland and OACS Ireland.